Senior Associate, Zurich
T +41 58 552 02 98
Louisa Galbraith is a senior associate in our Zurich office and a member of the firm’s IP team. She represents and advises clients in all aspects of IP and unfair competition law with a focus on patent and trademark law including pharmaceutical regulatory law. Her practice covers a broad range of industries, such as life sciences, retail, luxury goods and furniture.
Before joining MLL Legal Louisa worked as a junior associate for a leading Swiss law firm in Zurich, where she gained experience in the fields of international arbitration and copyright law. While attending the University of St. Gallen, she worked as a research assistant at the chair for public economic law particularly in the fields of procurement law, competition law, environmental law and regulation law.
Rankings & Awards
- Managing IP has recognized Louisa Galbraith as “Rising Star” in their 2022 edition
- “Louisa Galbraith is a rising star and one to watch in the near future” – Legal 500 EMEA, Healthcare and Life Sciences, 2022
- Louisa Galbraith has been recognised as a “Rising Star” in The Legal 500 EMEA, Healthcare and Life Sciences, 2022
- Managing IP has recognized Louisa Galbraith as “Rising Star” in their 2020/2021 edition
Deals & Cases
- Representation of Lindt & Sprüngli before the Swiss Federal Supreme Court against copies of the Lindt Gold Bunny offered by Lidl
Education & Admission
- Admitted to the bar in Switzerland (2017)
- University of St. Gallen, Master in Law and Economics (2015)
- University of St. Gallen, Bachelor in Law and Economics (2012)
- Patent Litigation 2023 Switzerland – Trends and Developments | 01.03.2023
- The Legal 500 Country Comparative Guides 2022 – Switzerland: Patent Litigation | 02.11.2022
- Patent Litigation 2022 Switzerland – Trends and Developments | 15.02.2022
- Little-known pitfall in application for paediatric extensions or paediatric SPCs | 14.02.2022
Find all publications by Louisa Galbraith on our website mll-legal.com.
Louisa Galbraith has been recognised as a “Rising Star” in The Legal 500 EMEA, Healthcare and Life Sciences, 2022
Patent Litigation 2023 Switzerland – Trends and DevelopmentsChambers and Partners, Global Practice Guides, Patent Litigation 2023, 01 March 2023
The Legal 500 Country Comparative Guides 2022 – Switzerland: Patent LitigationThe Legal 500 Country Comparative Guides 2022, November 2022
Patent Litigation 2022 Switzerland – Trends and DevelopmentsChambers and Partners, Global Practice Guides, Patent Litigation 2022, 15 February 2022
Little-known pitfall in application for paediatric extensions or paediatric SPCsInternational Law Office (ILO), 14 February 2022
IP Stars ranks Stefan Schröter and Louisa Galbraith as “Rising Stars” in their 2022 edition
MLL Legal successfully represents Lindt & Sprüngli against Lidl: Swiss Federal Supreme Court confirms trademark protection for the “Lindt Gold Bunny”
MLLStart! Barbecue-Party | 18 August 2022
MLL successfully represented Swisscom (Schweiz) AG in a patent infringement claim against the set-top-boxes of Swisscom TV
Intellectual Property in a nutshell – What is worthy of protection?
Little-Known Pitfall in Application for Paediatric Extensions or Paediatric SPCs
When filing applications for paediatric extensions and paediatric SPCs in Switzerland, it must be kept in mind that Switzerland is not a member state of the European Union and thus has a separate and independent system when it comes to the approval of medicinal products. Paediatric extensions and paediatric SPCs are only granted in Switzerland based on respective Swiss marketing authorizations issued by the competent authority Swissmedic. The relevant provisions in the Swiss Patent Act provide for some very particular conditions that the respective marketing authorizations must meet in order to serve as a basis for the grant of a paediatric extension or paediatric SPC. Those conditions are unique to Switzerland and therefore little-known abroad.
Electronic Signatures – A Simple Solution for Concluding Ip Contracts in the Digital Age?
If the current global pandemic had any positive impact on our daily lives, it is that we all have become more flexible: More people than before can work from wherever they like and be even more efficient by saving time and costs spent on travelling. Against the backdrop of these developments, it seems downright antiquated to continue signing letters, contracts, or other legal documents by hand. This is all the more the case as many companies now work completely paperless, not only for cost and efficiency reasons but also to promote sustainability. Therefore, it comes as no surprise that electronic signatures have become more and more popular recently.More
Switzerland issues new regulations to ensure national health care during the COVID 19 epidemic – The impact on the Life Sciences sector
On 3 April 2020, the Swiss Federal Council decided on new measures to coordinate the supply of essential medical supplies to combat Coronavirus. Those measures could have a significant impact on the Swiss market for pharmaceuticals and medical devices. The new instruments are defined in an amendment of the Swiss Ordinance on Measures to Combat the Coronavirus (COVID-19 Ordinance 2), which is based on the Swiss Epidemics Act. This article summarizes the new amendment and its impact on the Swiss Life Sciences sector.More